Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Clinical Trials

Background:

• Macular Telangiectasia type 2 (MacTel) is a progressive retinal degeneration.
• Revakinagene taroretcel (NT-501) is an encapsulated cell therapy delivering ciliary neurotrophic factor.
• Phase 2 trials indicated NT-501 slowed retinal degeneration in MacTel patients.

Purpose of the Study:

• To evaluate the efficacy and safety of NT-501 in treating MacTel.
• To assess the impact of NT-501 on photoreceptor loss (ellipsoid zone area).
• To investigate secondary outcomes including visual function and safety endpoints.

Main Methods:

• Two identically designed, multicenter, randomized sham-controlled phase 3 trials (NTMT-03-A and NTMT-03-B).
• Primary endpoint: Rate of ellipsoid zone area (EZA) loss over 24 months.
• Secondary endpoints: Retinal sensitivity, reading speed, NEI VFQ-25 scores, best-corrected visual acuity (BCVA), and adverse events.

Main Results:

• NT-501 significantly reduced EZA loss compared to sham in both trials (NTMT-03-A: -0.091 mm²/24 months, P<0.001; NTMT-03-B: -0.049 mm²/24 months, P=0.02).
• Changes in retinal sensitivity and reading speed were inconsistent between groups.
• No significant differences in NEI VFQ-25 scores, BCVA loss, or serious adverse events were observed; miosis and delayed dark adaptation were noted with NT-501.

Conclusions:

• NT-501 demonstrated statistically significant reduction in EZA loss in MacTel patients compared to sham.
• The findings support NT-501 as a potential therapeutic option for MacTel.
• Further monitoring for specific adverse events like miosis and delayed dark adaptation is warranted.